[go: up one dir, main page]

MXPA03004453A - Derivados de pirimidina. - Google Patents

Derivados de pirimidina.

Info

Publication number
MXPA03004453A
MXPA03004453A MXPA03004453A MXPA03004453A MXPA03004453A MX PA03004453 A MXPA03004453 A MX PA03004453A MX PA03004453 A MXPA03004453 A MX PA03004453A MX PA03004453 A MXPA03004453 A MX PA03004453A MX PA03004453 A MXPA03004453 A MX PA03004453A
Authority
MX
Mexico
Prior art keywords
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
MXPA03004453A
Other languages
English (en)
Inventor
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA03004453A publication Critical patent/MXPA03004453A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56One oxygen atom and one sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA03004453A 2000-11-22 2001-11-13 Derivados de pirimidina. MXPA03004453A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00125529 2000-11-22
PCT/EP2001/013084 WO2002042280A2 (en) 2000-11-22 2001-11-13 Pyrimidine derivatives

Publications (1)

Publication Number Publication Date
MXPA03004453A true MXPA03004453A (es) 2003-08-19

Family

ID=8170446

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03004453A MXPA03004453A (es) 2000-11-22 2001-11-13 Derivados de pirimidina.

Country Status (30)

Country Link
US (1) US6787539B2 (es)
EP (1) EP1339698A2 (es)
JP (1) JP3993100B2 (es)
KR (1) KR100571337B1 (es)
CN (1) CN1309710C (es)
AR (1) AR031486A1 (es)
AU (2) AU2002227921B2 (es)
BG (1) BG107840A (es)
BR (1) BR0115480A (es)
CA (1) CA2429570A1 (es)
CZ (1) CZ20031666A3 (es)
EC (1) ECSP034619A (es)
GT (1) GT200100232A (es)
HR (1) HRP20030362A2 (es)
HU (1) HUP0303045A3 (es)
IL (2) IL155705A0 (es)
JO (1) JO2307B1 (es)
MA (1) MA26967A1 (es)
MX (1) MXPA03004453A (es)
NO (1) NO324865B1 (es)
NZ (1) NZ525555A (es)
PA (1) PA8533501A1 (es)
PE (1) PE20020760A1 (es)
PL (1) PL366394A1 (es)
RU (1) RU2284997C2 (es)
SK (1) SK7612003A3 (es)
UY (1) UY27034A1 (es)
WO (1) WO2002042280A2 (es)
YU (1) YU39503A (es)
ZA (1) ZA200303517B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200402292T4 (tr) * 2000-01-31 2004-12-21 Pfizer Products Inc. PDE4 izozimlerinin inhibitörleri olarak pirimidin karboksamidler.
US8455489B2 (en) * 2003-11-10 2013-06-04 Exelixis, Inc. Substituted pyrimidine compositions and methods of use
JP4501015B2 (ja) 2004-03-17 2010-07-14 味の素株式会社 アミノピリミジン化合物の製造方法
JP4613501B2 (ja) 2004-03-17 2011-01-19 味の素株式会社 5−保護アミノピリミジン化合物の製造方法
US7280223B2 (en) * 2004-04-22 2007-10-09 Zygo Corporation Interferometry systems and methods of using interferometry systems
TW200608976A (en) 2004-05-08 2006-03-16 Neurogen Corp 4,5-disubstituted-2-aryl pyrimidines
BRPI0606187A2 (pt) 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
DE102005027150A1 (de) * 2005-03-12 2006-09-28 Bayer Healthcare Ag Pyrimidincarbonsäure-Derivate und ihre Verwendung
RU2279426C1 (ru) * 2005-03-15 2006-07-10 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) СПОСОБ ПОЛУЧЕНИЯ 2-(n-(1-АДАМАНТИЛ)ТИО)-4-(1-АДАМАНТИЛ)ОКСИ)-6-МЕТИЛПИРИМИДИНА
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド 2−メトキシ−5−(5−トリフルオロメチル−テトラゾール−1−イル)−ベンジル]−(2s−フェニル−ピペリジン−3s−イル)−アミンを含む医薬組成物
KR101032186B1 (ko) * 2008-12-31 2011-05-02 엘에스산전 주식회사 정격 미세 조정이 가능한 과전류 계전기
BR112012010220A2 (pt) * 2009-10-30 2021-02-23 Janssen Pharmaceutical N.V. piridinas fenóxi-substituídas como modulares do receptor opioide
RU2568434C2 (ru) * 2009-10-30 2015-11-20 Янссен Фармацевтика Нв Пиримидиновые соединения для использования в качестве модуляторов дельта-опиоидных рецепторов

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57131771A (en) * 1981-02-10 1982-08-14 Mitsubishi Yuka Yakuhin Kk Novel pyrimidine derivative
FR2536071B1 (fr) * 1982-11-12 1986-07-11 Sanofi Sa Sels acides de 2-piperazinopyrimidine, procede pour leur preparation et compositions pharmaceutiques en contenant
US4959368A (en) 1986-02-24 1990-09-25 Mitsui Petrochemical Industries Ltd. Therapeutic agent for neurological diseases
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
ATE364606T1 (de) 1993-12-29 2007-07-15 Merck Sharp & Dohme Substituierte morpholinderivate und ihre verwendung als arzneimittel
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5734081A (en) * 1994-08-05 1998-03-31 Warner-Lambert Company Arylthio compounds
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
TR200402292T4 (tr) * 2000-01-31 2004-12-21 Pfizer Products Inc. PDE4 izozimlerinin inhibitörleri olarak pirimidin karboksamidler.

Also Published As

Publication number Publication date
HUP0303045A2 (hu) 2003-12-29
KR20030060940A (ko) 2003-07-16
US6787539B2 (en) 2004-09-07
AU2792102A (en) 2002-06-03
WO2002042280A2 (en) 2002-05-30
HK1078079A1 (en) 2006-03-03
WO2002042280A3 (en) 2002-08-22
KR100571337B1 (ko) 2006-04-17
NO20032291L (no) 2003-05-21
JP2004514673A (ja) 2004-05-20
YU39503A (sh) 2006-05-25
AU2002227921B2 (en) 2006-02-16
ECSP034619A (es) 2003-06-25
HUP0303045A3 (en) 2004-03-29
PA8533501A1 (es) 2002-10-31
CA2429570A1 (en) 2002-05-30
RU2284997C2 (ru) 2006-10-10
RU2003117481A (ru) 2005-02-20
AR031486A1 (es) 2003-09-24
UY27034A1 (es) 2002-06-20
GT200100232A (es) 2002-07-04
CN1628103A (zh) 2005-06-15
SK7612003A3 (en) 2004-05-04
BR0115480A (pt) 2003-10-21
JP3993100B2 (ja) 2007-10-17
HRP20030362A2 (en) 2005-04-30
PL366394A1 (en) 2005-01-24
BG107840A (bg) 2004-01-30
NO324865B1 (no) 2007-12-17
IL155705A (en) 2008-11-26
NZ525555A (en) 2004-10-29
PE20020760A1 (es) 2002-08-21
EP1339698A2 (en) 2003-09-03
MA26967A1 (fr) 2004-12-20
JO2307B1 (en) 2005-09-12
IL155705A0 (en) 2003-11-23
ZA200303517B (en) 2004-08-10
NO20032291D0 (no) 2003-05-21
US20020099207A1 (en) 2002-07-25
CZ20031666A3 (cs) 2004-02-18
CN1309710C (zh) 2007-04-11

Similar Documents

Publication Publication Date Title
IL153754A0 (en) Pyrimidine derivatives
MXPA03001775A (es) Derivados de nucleosidos.
MXPA03002269A (es) Derivados de purina.
MXPA03000078A (es) Derivados de purina.
AU1041802A (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives
MXPA03005270A (es) Derivados de piperazina.
ZA200207331B (en) Ethylenediamine derivatives.
MXPA03002410A (es) 4-amino-quinazolinas.
AU3576801A (en) Pyrimidine compounds
MXPA03000939A (es) Derivados de imidazol.
EG23262A (en) Delta -pyrrolines.
MXPA03008140A (es) Amidas de acido benzofuran-2-carboxilico sustituidas.
MXPA03001591A (es) Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal.
MXPA03001877A (es) 2-guanidin-4-arilquinazolinas.
MXPA03004453A (es) Derivados de pirimidina.
MXPA03002668A (es) Guanidinas de sulfonilo.
ZA200205482B (en) Aminosulfonylbiphenyl derivatives.
ZA200206151B (en) Substituted amionomethyl-phenyl-cyclohexane derivatives.
MXPA03002411A (es) 4-amino-quinazolinas.
MXPA03005714A (es) Sulfamidotienopirimidinas.
MXPA03002737A (es) Derivados sustituidos de 1-aminobutan-3-ol.
MXPA03001269A (es) Nuevos derivados de aminociclohexano.
ZA200206150B (en) Aminomethyl-phenyl-cyclohexanone derivatives.
GB0112802D0 (en) Pyrimidine derivatives
MXPA03005494A (es) Benzoilpiridazinas.

Legal Events

Date Code Title Description
FG Grant or registration